III. AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

- 1-37. (canceled)
- 38. (currently amended) A method of effectively treating pain in humans or other mammals, comprising administering to a patient <u>a dosage form comprising</u> an analgesic combination consisting essentially of nabumetone and/or at least one pharmaceutically acceptable salt thereof; and oxycodone and/or at least one pharmaceutically acceptable salt thereof overlaps with the dosing interval of the oxycodone and/or at least one pharmaceutically acceptable salt thereof overlaps with the dosing interval of the oxycodone and/or at least one pharmaceutically acceptable salt thereof.
- 39. (currently amended) The method of claim 38, wherein the <u>dosage form is</u> nabumetone and/or at least one pharmaceutically acceptable salt thereof and the oxycodone and/or at least one pharmaceutically acceptable salt thereof are administered orally.
 - 40-45. (cancelled)
- 46. (previously presented) The method of claim 38, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof is present in an amount from about 2.5 mg to about 800 mg.
- 47. (previously presented) The method of claim 38, wherein the ratio of oxycodone and/or at least one pharmaceutically acceptable salt thereof to nabumetone and/or at least one pharmaceutically acceptable salt thereof is from about 0.0001:1 to about 1:1.

Appl. No. 10/056,348 Amdt. dated November 4, 2004 Reply to Office Action of July 6, 2004

- 48. (New) The method of claim 38, wherein the oxycodone is present in the pharmaceutically acceptable salt form.
- 49. (New) The method of claim 38, wherein the dosage form further comprises a sustained release carrier which provides a sustained release of the oxycodone and/or at least one pharmaceutically acceptable salt thereof.
- 50. (New) The method of claim 38, wherein the dosage form further comprises a sustained release carrier which provides a sustained release of the nabumetone and/or at least one pharmaceutically acceptable salt thereof; and oxycodone and/or at least one pharmaceutically acceptable salt thereof.